BETHESDA, MD, VerImmune, a venture-backed biotechnology company, announced the successful first closing of $4.5 million in its Pre-Series A financing round.
VerImmune, a venture-backed biotechnology company developing a groundbreaking Virus-inspired Particle (ViP) platform technology, announced the successful first closing of $4.5 million in its Pre-Series A financing round.
The financing was led by Beiley Biofund, an early-stage venture capital firm focused on cutting-edge technologies that address high unmet medical needs. New investors, including Dr. John Ballantyne, PhD, co-founder and former CSO at Aldevron, participated in the round, alongside returning investors Proxima Ventures, Mana Ventures, Gaingels, and others.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
By VC News Daily
Source: VC News Daily